| Autor: |
Panda, Tribikram, Rainchwar, Sujay, Halder, Rohan, Singh, Reema, Bhurani, Dinesh, Agrawal, Narendra |
| Předmět: |
|
| Zdroj: |
Annals of Hematology; Jan2024, Vol. 103 Issue 1, p347-349, 3p |
| Abstrakt: |
A letter published in the Annals of Hematology discusses the use of a low fixed dose of pembrolizumab in combination with gemcitabine, vinorelbine, and liposomal doxorubicin (Pembro100-GVD) as a salvage regimen for relapsed refractory classical Hodgkin's lymphoma (rrHL) and primary mediastinal B-cell lymphoma (rrPMBCL). The letter highlights the effectiveness of this regimen in achieving complete metabolic response and allowing for timely autologous hematopoietic stem cell transplantation (ASCT). The authors also note the financial toxicity associated with pembrolizumab and the potential for this regimen to be more accessible in low middle income countries (LMICs). The letter presents three cases treated with Pembro100-GVD, providing clinical characteristics, treatment, and outcomes for each patient. The authors conclude that Pembro100-GVD is a safe and affordable salvage regimen for rrHL and rrPMBCL, and they plan to conduct further studies to reduce healthcare costs and adverse effects while maintaining treatment efficacy. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink